Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OM-85 for moderate atopic dermatitis in children
NCT05222516Phase 2Terminated
- Sponsor
- OM Pharma
- Start
- Dec 2021
- Primary completion
- Jul 2023
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of OM-85 in atopic dermatitis (AD), sponsored by OM Pharma. Primary endpoints: Disease severity at 16 weeks and Disease severity at 24 weeks. Started Dec 2021; status: terminated.
02
Drugs
OM-85
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05222516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05222516.